1. Home
  2. IFRX vs NTWK Comparison

IFRX vs NTWK Comparison

Compare IFRX & NTWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • NTWK
  • Stock Information
  • Founded
  • IFRX 2007
  • NTWK 1997
  • Country
  • IFRX Germany
  • NTWK United States
  • Employees
  • IFRX N/A
  • NTWK N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • NTWK Computer Software: Prepackaged Software
  • Sector
  • IFRX Health Care
  • NTWK Technology
  • Exchange
  • IFRX Nasdaq
  • NTWK Nasdaq
  • Market Cap
  • IFRX 53.5M
  • NTWK 56.1M
  • IPO Year
  • IFRX 2017
  • NTWK 1998
  • Fundamental
  • Price
  • IFRX $1.26
  • NTWK $4.58
  • Analyst Decision
  • IFRX Strong Buy
  • NTWK
  • Analyst Count
  • IFRX 5
  • NTWK 0
  • Target Price
  • IFRX $7.40
  • NTWK N/A
  • AVG Volume (30 Days)
  • IFRX 486.5K
  • NTWK 116.0K
  • Earning Date
  • IFRX 11-07-2025
  • NTWK 11-12-2025
  • Dividend Yield
  • IFRX N/A
  • NTWK N/A
  • EPS Growth
  • IFRX N/A
  • NTWK 316.67
  • EPS
  • IFRX N/A
  • NTWK 0.25
  • Revenue
  • IFRX $191,224.00
  • NTWK $66,088,229.00
  • Revenue This Year
  • IFRX N/A
  • NTWK N/A
  • Revenue Next Year
  • IFRX $1,216.24
  • NTWK N/A
  • P/E Ratio
  • IFRX N/A
  • NTWK $18.00
  • Revenue Growth
  • IFRX 54.36
  • NTWK 7.65
  • 52 Week Low
  • IFRX $0.71
  • NTWK $2.14
  • 52 Week High
  • IFRX $2.82
  • NTWK $5.75
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 47.21
  • NTWK 51.09
  • Support Level
  • IFRX $1.14
  • NTWK $4.45
  • Resistance Level
  • IFRX $1.44
  • NTWK $4.63
  • Average True Range (ATR)
  • IFRX 0.14
  • NTWK 0.24
  • MACD
  • IFRX -0.04
  • NTWK -0.04
  • Stochastic Oscillator
  • IFRX 24.00
  • NTWK 33.33

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About NTWK NetSol Technologies Inc. Common Stock

NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.

Share on Social Networks: